In the era of new and mostly effective therapeutic protocols, multiple myeloma still tends to
be a hard-to-treat hematologic cancer. This hallmark of the disease is in fact a sequel to drug …

Small-cell lung cancer (SCLC), the highest malignant cancer amongst different types of lung
cancer, has the feature of lower differentiation, rapid growth, and poor survival rate. Despite …

Sphingosine kinase 1 (SPHK1) regulates cell proliferation and survival by converting
sphingosine to the signaling mediator sphingosine 1-phosphate (S1P). SPHK1 is widely …

The proteasome inhibitor bortezomib has proven to be invaluable in the treatment of
myeloma. By exploiting the inherent high immunoglobulin protein production of malignant …

Acute myeloid leukemia (AML) is an aggressive, heterogenous malignancy characterized by
clonal expansion of bone marrow-derived myeloid progenitor cells. While our current …

Although the over-expression of angiogenic factors is reported in diffuse large B-cell
lymphoma (DLBCL), the poor response to anti-VEGF drugs observed in clinical trials …

Sphingolipids, such as ceramide, sphingosine and sphingosine 1-phosphate (S1P) are
bioactive molecules that have important functions in a variety of cellular processes, which …

Abstract Sphingosine 1-phosphate (S1P) is a bioactive lipid that is formed by the
phosphorylation of sphingosine and catalysed by sphingosine kinase 1 (SK1) or …

Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma. Despite
being responsive to combination chemotherapy, median survival remains around 5 years …

Aim To further characterize the selectivity, mechanism-of-action and therapeutic efficacy of
the novel small molecule inhibitor, SKI-178. Methods Using the state-of-the-art Cellular …